Research · PMID 22607822 · Landmark study
Reviewed by Neal Rouzier, MD, Preventive Medicine · Sep 2026
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
Lancet (London, England) · August 2012 · Cholesterol Treatment Trialists' (CTT) Collaborators, B Mihaylova, J Emberson, L Blackwell, A Keech, et al.
What this study found
Statins reduce LDL cholesterol and prevent vascular events, but their net effects in people at low risk of vascular events remain uncertain. This meta-analysis included individual participant data from 22 trials of statin versus control (n=134,537; mean LDL cholesterol difference
Why this trial matters
CTT statin meta-analysis
How RAGMD uses this study
Clinical questions this paper informs
Synthesis lives on the evidence question — this page shows where the study sits in that analysis.
Primary study
Should adults take statins for primary cardiovascular prevention?
Meta-analyses of primary prevention trials show reduced major adverse cardiovascular events with statins in appropriately selected moderate-to-high-risk adults. Shared decision-making should weigh absolute risk reduction against side effects and patient preference.
Open evidence analysisSupporting literature
Is ApoB more useful than LDL-C for cardiovascular risk prediction?
Prospective cohorts and meta-analyses suggest ApoB may capture atherogenic particle burden better than LDL-C alone, particularly when triglycerides are elevated or LDL particles are discordant with LDL-C.
Open evidence analysisSupporting literature
Does elevated lipoprotein(a) independently increase cardiovascular risk?
Mendelian randomization and epidemiologic data support Lp(a) as a causal cardiovascular risk factor. Specific Lp(a)-lowering therapies are emerging but routine treatment beyond standard risk factor control awaits outcome trial confirmation.
Open evidence analysisSupporting literature
Does hormone therapy improve metabolic syndrome markers?
Menopausal hormone therapy may favorably affect some metabolic markers in selected women but is not a primary treatment for metabolic syndrome. Lifestyle and cardiometabolic risk management remain foundational.
Open evidence analysisSupporting literature
Can hormone therapy help insulin resistance in peri- and postmenopausal women?
Some studies show improved insulin sensitivity with estrogen-based therapy in early postmenopause, but results are not uniform across regimens. HRT should not replace evidence-based diabetes prevention or treatment.
Open evidence analysisSupporting literature
Does testosterone therapy affect blood pressure?
Testosterone effects on blood pressure are modest and inconsistent across trials. Monitoring blood pressure remains part of routine TRT follow-up, especially with fluid retention or erythrocytosis.
Open evidence analysisSupporting literature
Do therapies that raise HDL reduce cardiovascular events?
Trials of niacin and CETP inhibitors raised HDL without consistent reduction in cardiovascular events when added to statins, challenging the hypothesis that raising HDL alone is protective.
Open evidence analysisSupporting literature
Do omega-3 supplements prevent cardiovascular disease in the general population?
High-dose EPA (icosapent ethyl) reduced events in selected high-risk statin-treated patients in REDUCE-IT. General over-the-counter omega-3 supplements show inconsistent or null benefit in primary prevention populations.
Open evidence analysisSupporting literature
Should aspirin be used for primary cardiovascular prevention?
Current guidelines generally discourage routine aspirin for primary prevention in low-to-moderate-risk adults because bleeding harm offsets modest benefit. Select high-risk individuals may still be considered with shared decision-making.
Open evidence analysisSupporting literature
Should coronary artery calcium scoring guide statin decisions?
Coronary artery calcium can reclassify intermediate-risk patients and inform statin initiation when risk is uncertain. A score of zero may support deferring therapy in selected low-risk individuals with shared decision-making.
Open evidence analysis